Testing Multiple Treatments for Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with myasthenia gravis (MG) by a doctor.
- If you take MG medications, your doses must be stable (no recent changes).
- You do not have another autoimmune disease that would interfere with MG assessment.
- Your MG is not the most severe form (Class V, requiring breathing support).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.